Enhancing effect of new biological response modifier sulfoethylated (1→3)-β-D-glucan on antitumor activity of cyclophosphamide in the treatment of experimental murine leukoses

Experimental Oncology

Volumn 28, Issue 4, 2006, Pages 308-313

  Khalikova, T A ^a   Korolenko, T A ^a   Zhanaeva, S Ya ^a   Kaledin, V I ^b   Kogan, G ^c  

^a INSTITUTE OF PHYSIOLOGY   (Russian Federation)

^b INSTITUTE OF CYTOLOGY AND GENETICS   (Russian Federation)

^c INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Cathepsins B; Cyclophosphamide; L and D; Murine leukosis; Yeast glucan

Indexed keywords

ARGINYLARGINYLMETHYLCUMARILAMIDE; BIOLOGICAL RESPONSE MODIFIER; CATHEPSIN B; CATHEPSIN L; CYCLOPHOSPHAMIDE; FLUORESCENT DYE; LYSOSOME ENZYME; PHENYLARGINYLMETHYLCUMARILAMIDE; SULFOETHYL (1-3) BETA GLUCAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL INFILTRATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG POTENTIATION; ENZYME ACTIVITY; LEUKEMIA; LEUKOSIS; LOW DRUG DOSE; MACROPHAGE; MALE; MONOTHERAPY; MOUSE; MURINE LEUKEMIA VIRUS; NONHUMAN; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA-GLUCANS; CATHEPSIN B; CATHEPSIN L; CATHEPSINS; CYCLOPHOSPHAMIDE; CYSTEINE ENDOPEPTIDASES; DRUG SYNERGISM; IMMUNOLOGIC FACTORS; LEUKEMIA; MALE; MICE; MICE, INBRED DBA; NEOPLASM TRANSPLANTATION;

EID: 33846856516     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Kogan G, Šandula J, Korolenko TA, Falameeva OV, Poteryaeva ON, Zhanaeva SYa, Levina OA, Filatova TG, Kaledin VI. Increased efficiency of Lewis lung carcinoma chemotherapy with a macrophage stimulator - yeast carboxymethyl glucan. Int Immunopharmacol 2002; 2: 775-81.
2. Morton DL, Barth A. Local Therapy by Biological Agents. In: Biological Methods of Treatment of Oncological Diseases. DeVit VT, Hellman S, Rosenberg SA, eds. Moscow: Meditsina, 2002; 710-24 (in Russian).
3. Kleinerman US, Fiedler IJ. Macrophage Stimulation by Liposomes Containing Immunomodulators. In: Biological Methods of Treatment of Oncological Diseases. DeVit VT, Hellman S, Rosenberg SA, eds. Moscow: Meditsina, 2002; 853-64 (in Russian).
4. Williams DL. Overview of (1→3)-β-D-glucan immunobiology. Med Inflamm.1997; 6: 247-50.
5. Kogan G. (1→3,1→6)-β-D-Glucans of Yeasts and Fungi and Their Biological Activity. In: Studies in Natural Products Chemistry, Bioactive Natural Products. (part D) vol. 23. Attaur-Rahman, ed. Amsterdam: Elsevier, 2000; 107-52.
6. Miadoková E, Svidová S, Vlčková V, Kogan G, Rauko P. The role of microbial polysaccharides in cancer prevention and therapy. J Cancer Integr Med 2004; 2: 173-8.
7. Borchers AT, Keen CL, Gershwin ME. Minireview - mushrooms, tumors, and immunity: an update. Exp Biol Med 2004; 229: 393-406.
8. Bohn JA, BeMiller JN. (1→3)-β-D-Glucans as biological response modifiers: a review of structure-functional activity relationships. Carbohydr Polym 1995; 28: 3-14.
9. Suzuki M, Kikuchi T, Takatsuki F, Hamuro J. Curative effects of combination therapy with lentinan and interleukin-2 against established murine tumors, and the role of CD8-positive T cells. Cancer Immunol Immunother 1994; 38: 1-8.
10. Suzuki M, Iwashiro M, Takatsuki F, Kuribayashi K, Hamuro J. Reconstitution of anti-tumor effects of lentinan in nude mice: roles of delayed-type hypersensitivity reaction triggered by CD4-positive T cell clone in the infiltration of effector cells into tumor. Jpn J Cancer Res 1994; 85: 409-17.
11. Ng ML, Yap AT. Inhibition of human colon carcinoma development by lentinan from shiitake mushrooms (Lentinus edodes). J Altern Complement Med 2002; 8: 581-9.
12. Williams DL, Mueller A, Browder W. Glucan-based macrophage stimulators. A review of their anti-infective potential. Clin Immunother 1996; 5: 392-9.
13. Browder W, Williams D, Pretus H, Olivero G, Enrichens F, Mao P, Franchello A. Beneficial effect of enhanced macrophage function in trauma patient. Ann Surg 1990; 211: 605-13.
14. Pretus HA, Ensley HE, McNamee RB, Jones EL, Browder IW, Williams DL. Isolation, physicochemical characterization and preclinical efficacy evaluation of soluble scleroglucan. J Pharmacol Exp Ther 1991; 257: 500-10.
15. Sherwood ER, Williams DL, DiLuzio NR. Glucan stimulates production of antitumor cytolytic/cytostatic factor(s) by macrophages. J Biol Response Modif 1986; 5: 504-26.
16. Sherwood ER, Williams DL, McNamee RB, Jones EL, Browder IW, DiLuzio NR. In vitro tumoricidal activity of resting and glucan-activated Kupffer cells. J Leukocyte Biol 1987; 42: 69-75.
17. Machová E, Kogan G, Alföldi J, Šoltés L, Šandula J. Enzymatic and ultrasonic depolymerization of carboxymethylated β-1,3-D-glucans derived from Saccharomyces cerevisiae. J Appl Polym Sci 1995; 55: 699-704.
18. Khalikova TA, Zhanaeva SYa, Korolenko TA, Kaledin VI, Kogan G. Regulation of activity of cathepsins B, L, and D in murine lymphosarcoma model at a combined treatment with cyclophosphamide and yeast polysaccharide. Cancer Lett 2005; 223: 77-83.
19. Kogan G, Alföldi J, Master L. Carbon-13 NMR spectroscopic investigation of two yeast cell wall β-D-glucans. Biopolymers 1988; 27: 1055-63.
20. Chorvatovičová D, Kováčiková Z, Šandula J, Navarová J. Protective effect of sulfoethylglucan against hexavalent chromium. Mutat Res 1993; 302: 207-11.
21. Kaledin VI, Nikolin VP, Semenova LA, Godovikov AA. L1210/1 - a novel sub-strain of L1210 leukosis with modified growth characteristics. Exp Oncol 1991; 13: 43-4 (in Russian).
22. Svechnikova IG, Korolenko TA, Stashko JuF, Kaledin VI, Nikolin VP, Nowicky JW. The influence of Ukrain on the growth of HA-1 tumor in mice: the role of cysteine proteinases as markers of tumor malignancy. Drugs Exp Clin Res 1998; 24: 261-9.
23. Kaledin VI, Nikolin VP, Galyamova MR, Vasil'eva ED, Baimak TY, Popova NA. High apoptosis-inducing and antitumor activities of the products of biological but not chemical cyclophosphamide activation. Dokl Biol Sci 2002; 386: 426-9 (in Russian).
24. Ross GD, Cain JA, Myones BL, Newman SL, Lachmann PJ. Specificity of membrane complement receptor type three (CR3) for beta-glucans. Complement 1987; 4: 61-74.
25. Zimmerman JW, Lindermuth J, Fish PA, Palace GP, Stevenson TT, DeMong DE. A novel carbohydrate-glycosphingolipid interaction between a beta-(1-3)-glucan immunomodulator, PGG-glucan, and lactosylceramide of human leukocytes. J Biol Chem 1998; 273: 22014-20.
26. Rice PJ, Kelley JL, Kogan G, Ensley HE, Kalbfleisch JH, Browder IW, Williams DL. Human monocyte scavenger receptors are pattern recognition receptors for (1→ 3)-β-D-glucans. J Leukocyte Biol 2002; 72: 140-6.
27. Brown GD, Gordon S. Immune recognition: a new receptor for β-glucans. Nature 2001; 413: 36-7.
28. Thornton B, Vetvicka V, Pitman M, Goldman RC, Ross GD. Analysis of the sugar specificity and molecular location of the β-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J Immunol 1996; 156: 1235-46.
29. Di Renzo L, Yefenof E, Klein E. The function of human NK cells is enhanced by β-glucan, a ligand of CR3 (CD11b/ CD18). Eur J Immunol 1991; 21: 1755-8.
30. Vetvicka V, Thornton BP, Wieman TJ, Ross GD. Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and β-glucan-primed CR3 (CD11b/CD18). J Immunol 1997; 19: 599-605.
31. Vetvicka V, Yvin JC. Effects of marine β-1,3 glucan on immune reactions. Int Immunopharmacol 2004; 4: 721-30.
32. Kougias P, Wei D, Rice PJ, Ensley HE, Kalbfleisch J, Williams DL, Browder IW. Normal human fibroblasts express pattern recognition receptors for fungal (1→3)-β-D-glucans. Infect Immun 2001; 69: 3933-8.
33. 3. Immunology 1988; 63: 319-24.
34. Majtán J, Kogan G, Kováčová E, Bíliková K, Šimúth J. Stimulation of TNF-α release by fungal cell wall polysaccharides. Z Naturforsch 2005; 60c: 921-6.